Comparative Pharmacology
Head-to-head clinical analysis: INDOCIN SR versus ORUDIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOCIN SR versus ORUDIS.
INDOCIN SR vs ORUDIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins, which mediate inflammation, pain, and fever. It also has a direct effect on renal blood flow and platelet aggregation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
75 mg orally once daily, extended-release capsules.
Oral: 50 mg three times daily or 75 mg twice daily; maximum 300 mg/day. Topical: Apply 2-4 g of gel or cream to affected area four times daily. Intramuscular: 50-100 mg every 4-6 hours; maximum 200 mg/day.
None Documented
None Documented
Terminal half-life is 4.5 hours (range 2.6-11.2 hours) in young adults; prolonged in elderly (up to 16 hours) and in patients with renal or hepatic impairment.
Terminal half-life: ~1.5-2 hours for immediate-release; 30-50% increase in elderly due to reduced clearance. Clinical context: short half-life requires frequent dosing for sustained analgesia; no accumulation with q6-8h dosing.
Approximately 50% renal (as unchanged drug and metabolites, primarily glucuronide conjugates), 33% biliary/fecal. Indomethacin undergoes enterohepatic recirculation.
Renal: ~60% as metabolites (glucuronides of ketoprofen and hydroxylated metabolites); fecal: ~30% (biliary excretion); unchanged drug: <1% in urine.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)